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OBJECTIVE—Hepatic glucokinase (GCK) is a key regulator of
glucose storage and disposal in the liver, where its activity is
competitively modulated, with respect to glucose, by binding to
glucokinase regulatory protein (GCKR) in the presence of fruc-
tose 6-phosphate. Genome-wide association studies for type 2
diabetes identiﬁed GCKR as a potential locus for modulating
triglyceride levels. We evaluated, in a general French population,
the contribution of the GCKR rs1260326-P446L polymorphism to
quantitative metabolic parameters and to dyslipidemia and hyper-
glycemia risk.
RESEARCH DESIGN AND METHODS—Genotype effects of
rs1260326 were studied in 4,833 participants from the prospec-
tive DESIR (Data from an Epidemiological Study on the Insulin
Resistance syndrome) cohort both at inclusion and using the
measurements at follow-up.
RESULTS—The minor T-allele of rs1260326 was strongly asso-
ciated with lower fasting glucose (1.43% per T-allele; P  8 
10
13) and fasting insulin levels (4.23%; P  3  10
7), lower
homeostasis model assessment of insulin resistance index
(5.69%; P  1  10
8), and, conversely, higher triglyceride
levels (3.41%; P  1  10
4) during the 9-year study. These
effects relate to a lower risk of hyperglycemia (odds ratio [OR]
0.79 [95% CI 0.70–0.88]; P  4  10
5) and of incident cases
during the study (hazard ratio [HR] 0.83 [0.74–0.95]; P  0.005).
Moreover, an additive effect of GCKR rs1260326(T) and GCK
(30G) alleles conferred lower fasting glycemia (P  1  10
13),
insulinemia (P  5  10
6), and hyperglycemia risk (P  1 
10
6).
CONCLUSIONS—GCKR-L446 carriers are protected against
type 2 diabetes despite higher triglyceride levels and risk of
dyslipidemia, which suggests a potential molecular mechanism
by which these two components of the metabolic syndrome can
be dissociated. Diabetes 57:2253–2257, 2008
T
he enzyme glucokinase (GCK) is the major glu-
cose sensor of the pancreatic -cells, where it
adapts insulin secretion to blood glucose levels.
GCK also participates in regulating glycogen
synthesis and gluconeogenesis in the liver (1). GCK activ-
ity is allosterically controlled in hepatocytes by the glu-
cokinase regulatory protein (GCKR), which reversibly
binds to GCK and inhibits its activity in the presence of
fructose 6-phosphate. GCKR acts as a competitive inhibi-
tor of GCK with respect to glucose and is suppressed by
the speciﬁc metabolite fructose 1-phosphate (2).
In GCKR-deﬁcient mice, the disruption of this regulation
and the subsequent decrease in GCK activity leads to
altered glucose metabolism and impaired postprandial
glycemic control (3,4), although no change in fasting blood
glucose concentration is observed. Adenoviral-mediated
hepatic overexpression of GCKR in mice with high-fat
diet–induced diabetes improves fasting and glucose-
induced glycemia and leads to a concomitant increase in
insulin sensitivity and triglyceride levels and a decrease in
leptin levels (5). Heterozygous mutations in GCK resulting
in a reduction of enzymatic activity are responsible for a
subtype of monogenic diabetes (maturity-onset diabetes of
the young-2) (1,6). Previous genetic studies at the GCKR
locus have not reported intragenic mutations associated
with type 2 diabetes in humans (7,8).
The Diabetes Genetics Initiative (DGI) genome-wide
association study for type 2 diabetes and quantitative
metabolic traits reported an intronic polymorphism of
GCKR (rs780094) explaining interindividual variability in
plasma triglyceride (TG) levels and a trend toward asso-
ciation with lower fasting glycemia, less insulin resistance,
and lower risk for type 2 diabetes (9). The HapMap II CEU
data (www.hapmap.org) showed that rs780094 is in strong
linkage disequilibrium (r
2  0.932) with a non-synony-
mous GCKR variant (Pro446Leu, rs1260326) that we pre-
viously identiﬁed by the DNA sequencing of French
individuals (7). Marju Orho-Melander and colleagues re-
cently communicated their ﬁne-mapping data showing the
strongest signal for TG levels at the coding single nucleo-
tide polymorphism (SNP) (rs1260326; P  1.5  10
9),
with lesser associations to fasting glycemia and insulin
sensitivity (M. Orho-Melander, O. Melander, V. Lyssenko,
for the DGI, unpublished data). Similar ﬁndings for the
intronic variant rs780094 were reported in a Danish pop-
ulation (10).
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DIABETES, VOL. 57, August 2008 2253We evaluated the association between GCKR rs1260326-
P446L and TG levels in a middle-aged general French
population with a follow-up of 9 years (11). Given the key
role of GCKR in hepatic glucose metabolism, we also
assessed the effect of rs1260326 on glucose homeostasis
parameters and on the risk of impaired fasting glycemia
and type 2 diabetes. Furthermore, as we previously
showed a strong association of the GCK (30A) promoter
variant (rs1799884) to increased fasting glycemia and type
2 diabetes risk in the same study cohort (11), we also
assessed possible additive effects of GCKR rs1260326-
P446L and GCK 30G/A SNPs on fasting glucose, insulin,
TG levels, and hyperglycemia risk.
RESEARCH DESIGN AND METHODS
Participants in the Data from an Epidemiological Study on the Insulin
Resistance syndrome (DESIR) study were clinically and biologically evaluated
at inclusion and at 3-, 6-, and 9-year follow-up visits (11,12). All subjects
included in the study signed an informed consent form, and the protocol was
approved by the ethics committee of Bice ˆtre Hospital. Because ethnic origin
could not be legally documented at the beginning of the DESIR study, the
proportion of subjects having non-European ancestry was estimated as 0.30%
by a STRUCTURE analysis of 328 SNPs in 654 selected subjects, as previously
published (11). Moreover, all individuals born outside France were excluded
from this study. Overall, 4,833 individuals of the DESIR cohort were analyzed,
of whom 3,877 were examined during the entire 9-year study.
Glycemic status was deﬁned according to 1997 American Diabetes Asso-
ciation criteria: normoglycemia, deﬁned as fasting plasma glucose (FPG) 6.1
mmol/l without hypoglycemic treatment; impaired fasting glucose (IFG),
deﬁned as FPG between 6.1 and 6.99 mmol/l without hypoglycemic treatment;
and type 2 diabetes, deﬁned as FPG 7.0 mmol/l and/or treatment with
antidiabetic agents.
Dyslipidemia was deﬁned according to World Health Organization criteria:
TG 1.7 mmol/l, HDL cholesterol 0.9 mmol/l for men or 1.0 mmol/l for
women, or current treatment with lipid-lowering drugs. Biological parameters
were assessed as previously described (11,12).
SNP genotyping. Genotyping of rs1260326 was performed using TaqMan
Technology (Applied Biosystems, Foster City, CA). A successful genotyping
rate of 99% was achieved in the whole cohort sample. Duplicate samples were
assayed with a concordance rate 99%. The genotype distribution of
rs1260326 was in Hardy-Weinberg equilibrium (P  0.05). The rs1799884 SNP
was genotyped as previously reported (11).
Statistical analyses. The effect of the rs1260326 genotype on quantitative
parameters was assessed in untreated individuals both at baseline and using
repeated measures at 3-, 6-, and 9-year follow-up visits (11). All quantitative
traits were log transformed before analyses and adjusted for age, sex, and
BMI. We used linear regression models for analyses at baseline and mixed
models for analyses of repeated measures.
The risk of hyperglycemia, type 2 diabetes, and dyslipidemia at the end of
the study was assessed by logistic regression models, including age, sex, and
BMI as covariates. Cox proportional hazards regression models were used to
estimate the genotype effects on the incidence of hyperglycemia, type 2
diabetes, and dyslipidemia. The models included sex and BMI as covariates.
Mean BMI was estimated for all available measures for censored individuals
and for all available measures before diagnosis for case subjects. Survival time
was considered equivalent to an individual’s age.
The additive effect of GCKR rs1260326 and GCK (30G/A) rs1799884 on
FPG, insulin, and TG levels was assessed in individuals untreated at baseline
by a linear regression model including the number of risk alleles, age, sex, and
BMI as covariates in order to quantify the combined genotype effect per
supplementary at-risk allele (as previously described [11]). In the same way,
the additive effect of both variants on the risk of hyperglycemia at the end of
the 9-years’ follow-up was explored using a logistic regression model. In these
analyses, we considered the T-allele of GCKR rs1260326 and the G-allele of
GCK rs1799884 as protective against hyperglycemia and type 2 diabetes. We
then compared the models, including the number of risk alleles as a covariate
to the null model including no SNP covariate, by using likelihood ratio. All
statistical analyses were performed using R (version 2.6.0) combined with
mgcv, survival, and nlme packages.
RESULTS
The GCKR rs1260326-P446L variant was genotyped in a
total of 4,833 participants of the DESIR study and showed
an overall minor allele frequency of 43.9%. We ﬁrst ana-
lyzed the relationship of rs1260326 with lipid and glucose
homeostasis parameters in 4,363 individuals who were not
treated with hypoglycemic or lipid-lowering drugs at in-
clusion. The minor T-allele of rs1260326 was associated
with increased TG levels both at baseline (P  5  10
4;
Table 1) and from the repeated measures during the 9-year
follow-up (P  1  10
4; Table 2). No associations were
observed with total, HDL, or LDL cholesterol levels (Table
1).
Conversely, the same T-allele of rs1260326 was strongly
associated with lower FPG (P  9  10
9) and fasting
serum insulin (P510
5) and a lower homeostasis model
assessment of insulin resistance (HOMA-IR) index (P 
4  10
6) at baseline (Table 1). The genotype effect was
even more signiﬁcant when repeated measures over the
9-year study were analyzed for these parameters (P  8 
10
13 for FPG, P  3  10
7 for insulin, and P  1  10
8
for HOMA-IR) (Table 2). No effect on the -cell insulin
secretion index was seen in this population, in agreement
with the hypothesis that the GCKR coding variant would
TABLE 1
Anthropometric and metabolic characteristics of participants not treated with either hypoglycemic or lipid-lowering drugs at
inclusion in the study, with data stratiﬁed according to GCKR rs1260326 genotype
CC CT TT Padditive % (95% CI)
n 4,363 1,383 2,125 855
Sex ratio (male/female) 2,135/2,228 666/717 1,044/1,081 425/430
Age (years) 46.5  9.79 46.3  9.83 46.7  9.8 46.5  9.69
BMI (kg/m²) 24.5  3.77 24.4  3.64 24.6  3.94 24.5  3.53 0.8 0.09 (0.50 to 0.68)
Waist-to-hip ratio 0.85  0.09 0.85  0.09 0.85  0.09 0.85  0.09 0.2 0.16 (0.42 to 0.09)
Fasting glucose (mmol/l) 5.31  0.68 5.37  0.74 5.30  0.64 5.24  0.68 9  10
9 1.27 (1.70 to 0.84)
Fasting insulin (pmol/l) 46.0  29.07 46.8  27.49 46.8  31.47 42.9  24.86 5  10
5 3.90 (5.72 to 2.04)
HOMA-B 89.7  61.27 87.6  50.89 90.7  57.29 90.9  82.58 0.9 0.11 (2.19 to 2.46)
HOMA-IR 1.82  1.27 1.88  1.33 1.84  1.31 1.68  1.07 4  10
6 5.45 (7.66 to 3.18)
Total cholesterol (mmol/l) 5.74  1.03 5.75  1.04 5.73  1.02 5.74  1.03 0.5 0.24 (0.94 to 0.46)
LDL cholesterol (mmol/l) 3.58  0.92 3.61  0.95 3.56  0.91 3.57  0.94 0.2 0.75 (1.82 to 0.33)
HDL cholesterol (mmol/l) 1.64  0.43 1.64  0.43 1.64  0.43 1.63  0.41 0.8 0.14 (0.86 to 1.14)
TG (mmol/l) 1.16  1.08 1.12  1.2 1.17  1.08 1.21  0.83 5  10
4 3.69 (1.61 to 5.82)
Data are means  SD or n unless otherwise indicated. The P values indicated are nominal P-values. % is the percentage of variation of the
trait per supplementary minor T-allele. P values and % are from linear regression models adjusted for age, sex, and BMI. HOMA-B,
homeostasis model assessment of -cell function; HOMA-IR, homeostasis model assessment of insulin resistance; TG, triglycerides.
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hepatic glucose metabolism. The characteristics of the 470
individuals treated with hypoglycemic and/or lipid-lower-
ing medications or for whom data were unknown and
were thus excluded from the quantitative trait analyses are
shown in online appendix Table 1 (available online at
http://dx.doi.org/db07-1807).
Furthermore, the rs1260326 T-allele was strongly asso-
ciated with a decreased risk of hyperglycemia in the whole
cohort at the end of the study (OR 0.79 [95% CI 0.70–0.88];
P  4  10
5) and with decreased incidence during the
9-year follow-up (based on 516 incident cases of hypergly-
cemia, HR 0.83 [95% CI 0.74–0.95]; P  0.005) (Table 3).
Similarly, the rs1260326 T-allele conferred a signiﬁcantly
lower risk of type 2 diabetes in this population (OR 0.79
[0.65–0.95] at the end of the study, P  0.01).
With regard to dyslipidemia, according to World Health
Organization criteria, 2,102 subjects showed abnormal TG
or HDL cholesterol proﬁles or were treated with a lipid-
lowering drug at least once during the study, and 2,731
remained normolipidemic. The rs1260326 T-allele was
modestly associated with dyslipidemia risk (OR 1.12 [95%
CI 1.02–1.22]; P  0.01) (Table 3). When considering
hypertriglyceridemia (TG 1.7 mmol/l) alone, a similar
risk effect was observed (1.12 [1.01–1.23]; P  0.03 [data
not shown]).
We also analyzed the combined effects of GCKR
rs1260326-P446L with the GCK 30G/A SNP: when com-
paring carriers of four risk alleles with the reference group
with zero or one allele, fasting glycemia was signiﬁcantly
lower by 0.20 mmol/l (P  1  10
13) (Fig. 1A), fasting
insulinemia was signiﬁcantly lower by 6.19 pmol/l (P  5 
10
6) (data not shown), and hyperglycemia (including
type 2 diabetes) risk decreased to OR 0.49 (P  1  10
6)
(Fig. 1B). Models including the number of risk alleles as a
covariate were signiﬁcantly better than those with no SNP
covariate (P  1.5  10
13 for fasting glucose, P  5.4 
10
6 for fasting insulin, and P  1.2  10
6 for hypergly-
cemia or type 2 diabetes risk). As expected, no additive
effect on TG levels was observed when combining the risk
alleles of GCK 30G/A and GCKR rs1260326-P446L.
DISCUSSION
Our data show that the GCKR P446L polymorphism is
associated with increased TG levels in a general French
population, which extends previous ﬁndings from intronic
tagged SNPs in Finnish and Swedish populations (9) and in
the Danish population-based Inter99 study (10). The minor
T-allele of rs1260326-P446L explained 0.2% of the TG
variance in our study population, showing a more modest
effect than that reported in the Scandinavian samples,
where the T-allele of rs780094 explained between 0.4–1.2%
of the trait variance (ref. 9 and M. Orho-Melander, O.
Melander, V. Lyssenko, for the DGI, unpublished data). In
the Northern European populations investigated for the
GCKR intronic variant, the mean BMI values were higher
than in the DESIR participants (26–30 vs. 24.5 kg/m
2,
respectively), and the TG levels showed more variability
according to genotypes (9,10). This may explain the dif-
ferences in the degree of association for TG levels be-
tween the French DESIR study and other Northern
European populations.
Conversely, the nonsynonymous rs1260326-P446L vari-
ant has a much stronger effect on the glucose homeostasis
parameters in the DESIR cohort than in the Finnish,
Swedish, and Danish populations, although the effects
were seen in the same direction (9,10). The lower fasting
glycemia in the T-allele carriers (even greater than the
levels seen for the GCK 30G/A promoter variant in the
TABLE 2
Effects of GCKR rs1260326 on TG levels and glucose homeostasis parameters using up to four repeated measurements over the 9-year
follow-up study
Number of
observations P % (95% CI) Overall mean  SD
CC CT TT
Fasting plasma glucose (mmol/l)
additive 13,941 8  10
13 1.43 (1.81 to 1.04) 5.41  0.70 5.34  0.69 5.27  0.64
dominant 2  10
10 1.92 (2.50 to 1.33)
recessive 2  10
7 1.85 (2.54 to 1.17)
Fasting serum insulin (pmol/l)
additive 13,915 3  10
7 4.23 (5.80 to 2.63) 52.9  37.48 51.5  36.66 47.9  31.57
dominant 3  10
5 5.19 (7.54 to 2.77)
recessive 3  10
5 6.13 (8.86 to 3.32)
HOMA-IR
additive 12,042 1  10
8 5.69 (7.57 to 3.79) 2.15  1.75 2.06  1.70 1.90  1.53
dominant 1  10
6 7.20 (9.98 to 4.34)
recessive 7  10
6 7.87 (11.10 to 4.52)
HOMA-B
additive 12,031 1 0.04 (1.99 to 1.95) 101.3  69.15 103.1  80.51 101.4  77.25
dominant 0.7 0.57 (2.39 to 3.61)
recessive 0.6 0.90 (4.30 to 2.63)
Fasting plasma TG (mmol/l)
additive 13,955 1  10
4 3.41 (1.68 to 5.16) 1.12  0.87 1.19  0.97 1.21  0.73
dominant 1  10
3 4.24 (1.61 to 6.94)
recessive 1  10
3 5.00 (1.90 to 8.19)
The P values indicated are nominal P values. %, percentage of variation of the trait per supplementary minor T-allele. P values and % are
from mixed models adjusted for age, sex, and BMI. HOMA-B, homeostasis model assessment of -cell function; HOMA-IR, homeostasis model
assessment of insulin resistance; TG, triglycerides.
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DIABETES, VOL. 57, August 2008 2255same cohort [11]) is likely due to improved hepatic glu-
cose disposal and insulin sensitivity; this may result from
a direct effect on the hepatic glucose metabolism, as
GCKR closely interacts with GCK in the hepatocytes,
depending on glucose concentrations, to regulate the
amount and activity of GCK and, consequently, the hepatic
glucose disposal (13).
Whatever the mechanism of action of GCKR genetic
variation, it leads to a lower risk of fasting hyperglycemia
and type 2 diabetes in this study. Both GCKR-P446L and
GCK 30G/A SNPs strongly modulate FPG, with signiﬁ-
cant additive effects (they lower FPG by 0.20 mmol/l in the
general population and decrease hyperglycemia risk), sup-
porting the hypothesis that these frequent variants may
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2256 DIABETES, VOL. 57, August 2008have a non-negligible impact on human health. Indeed,
there is strong evidence that even small changes in FPG,
well below the IFG threshold of 6.1 mmol/l, may be
associated with risk of cardiovascular morbidity and mor-
tality (14–16). In this context, the GCK (30A) allele was
previously shown to be associated with type 2 diabetes
and increased risk for coronary heart diseases in both
diabetic and nondiabetic samples (17).
It is tempting to propose that the P446L variant replac-
ing a residue conserved between mammals might be the
causative variant. However, one previous study having
investigated the sensitivity of the GCKR-L446 mutant to
fructose 6- and 1-phosphate, using rat GCKR, did not
report any effect compared with the wild-type protein (7).
Differential regulatory features between human and rat
GCKR (18) could have masked a functional consequence
of the L446 variant, or a more subtle, distinct defect acting
on either GCK or another target protein remains to be
discovered. Alternatively, other SNPs may be etiological,
as the common P446L variant lies in a large haplotype
block covering at least 400 Kb of genomic sequence
(www.hapmap.org).
In conclusion, our study in the DESIR prospective
cohort shows that carriers of the GCKR-L446 variant have
lower fasting glycemia and insulin resistance and are
protected against the development of diabetes despite
higher TG levels and a risk of dyslipidemia. This suggests,
for the ﬁrst time, a molecular mechanism by which these
two components of the so-called metabolic syndrome can
be dissociated. Based on rodent models, such as the
adenoviral-mediated hepatic overexpression of GCK or
GCKR in mice with diet-induced diabetes (5,19), more
active GCKR may result in improved interaction with GCK,
leading to more efﬁciently releasable pools of GCK en-
zyme, with subsequent beneﬁcial effects on glucose me-
tabolism but otherwise with a concomitant alteration of
lipid proﬁle.
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